Drugs / ZAMAPORVINT
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03447470 | Mar 2019 → Sep 2023 | cancer | Redx Pharma Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04907851 | Dec 2021 → Nov 2023 | cancer | Redx Pharma Ltd | Completed | No outcome recorded |
| Phase 2 | NCT04907539 | Nov 2021 → Apr 2024 | colorectal cancer | Redx Pharma Ltd | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZAMAPORVINT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314431 ↗ |
| Known as | RXC004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03447470 ↗ |
| Action | Inhibit | “inhibits porcupine (PORCN)” NCT03447470 ↗ |
| Modality | Small molecule | — CHEMBL5314431 ↗ |
| Route | Oral | “RXC004 is taken orally” NCT03447470 ↗ |
| Target | PORCN | “inhibits porcupine (PORCN)” NCT03447470 ↗ |